A Proof of Concept Study for 6 Month Treatment in Patients With C3 Glomerulopathy (C3G)



Status:Recruiting
Healthy:No
Age Range:17 - 65
Updated:1/11/2019
Start Date:June 12, 2018
End Date:October 2019
Contact:Clinical Operations
Email:C3GTrialInquiries@achillion.com
Phone:203-752-5566

Use our guide to learn which trials are right for you!

A Phase 2, Proof-of-Concept, Randomized, Double-Blinded, Placebo-Controlled Study of ACH-0144471 Treatment for 6 Months in Patients With C3 Glomerulopathy (C3G)

The primary purpose of this proof of concept clinical study is to evaluate the efficacy and
safety of the study drug, ACH-0144471, in participants who have been diagnosed with either
C3GN or dense deposit disease (DDD) based on renal biopsy. Participants will be randomized
1:1 to receive either study drug ACH-0144471 or placebo for a period of 6 months.


Inclusion Criteria:

- Initial diagnosis of C3GN or DDD 3 months prior to the first dose of study drug and
prior to age 55 years.

- Confirmation of DDD or C3 glomerulonephritis (C3GN) diagnosis by review of a renal
biopsy obtained no more than 30 days (and preferably within 2 weeks) of first dose of
study drug by the study's central pathology laboratory

- Clinical evidence of ongoing disease based on significant proteinuria, defined as ≥1
g/day of protein in a 24-hour urine, attributable to C3G disease in the opinion of the
Principal Investigator (PI), and present prior to study entry and confirmed during
Screening

- Must be willing to comply with study-specific vaccination requirements, including
those for N. meningitidis, H. influenzae, and S. pneumonia

Exclusion Criteria:

- Have a history or presence of any clinically relevant co-morbidities that would make
the participant inappropriate for the study

- Have ever received ACH-0144471

- Have more than 50% fibrosis or more than 50% of glomeruli with cellular crescents on
the pre-treatment renal biopsy

- Have an estimated GFR <30 mL/min for participants19 years of age and older (based on
CKD-EPI creatinine equation [2009]), and <30 mL/min/1.73 m2 for participants <19 years
old (based on "Bedside Schwartz" equation [2009]) at the time of screening or at any
time over the preceding four weeks

- Have C4 levels <80% lower limit of normal (LLN)

- Is a renal transplant recipient or receiving renal replacement therapy

- Have a history of a major organ transplant (e.g., heart, lung, kidney, liver) or
hematopoietic stem cell/marrow transplant

- Have evidence of monoclonal gammopathy of unclear significance (MGUS), infections,
malignancy, autoimmune diseases, or other conditions to which C3G may be secondary

- Have other renal diseases that would interfere with interpretation of the study

- Have comorbid conditions that would interfere with completion of the trial (e.g.,
malignancies, congestive heart failure, recent myocardial infarction)

- Females who are pregnant, nursing, or planning to become pregnant during the study or
within 90 days of study drug administration

- Have a history of febrile illness, a body temperature >38°C, or other evidence of a
clinically significant active infection, within 14 days prior to study drug
administration

- Have evidence of human immunodeficiency virus (HIV) (positive serology for HIV
antibody [HIV Ab]), hepatitis B infection (positive hepatitis B surface antigen
[HbsAg]), or hepatitis C infection (positive anti-HCV antibody [HCV Ab]) at Screening
or historically

- Have any of the following laboratory abnormalities at screening:

- Alanine transaminase (ALT) > upper limit of normal (ULN)

- Aspartate aminotransferase (AST) > ULN

- Absolute neutrophil counts (ANC) <1,000/μL

- Total bilirubin >1.5× ULN

- Indirect bilirubin > ULN

- Any laboratory abnormality that, in the opinion of the PI, would make the
participant inappropriate for the study

NOTE: Additional inclusion/exclusion criteria will apply, per protocol
We found this trial at
10
sites
116th St and Broadway
New York, New York 10027
(212) 854-1754
Principal Investigator: Gerald Appel
Columbia University In 1897, the university moved from Forty-ninth Street and Madison Avenue, where it...
?
mi
from
New York, NY
Click here to add this to my saved trials
1200 Moursund Street
Houston, Texas 77030
(713) 798-4951
Baylor College of Medicine Baylor College of Medicine in Houston, the only private medical school...
?
mi
from
Houston, TX
Click here to add this to my saved trials
101 Jessup Hall
Iowa City, Iowa 52242
(319) 335-3500
Principal Investigator: Carla Nester
University of Iowa With just over 30,000 students, the University of Iowa is one of...
?
mi
from
Iowa City, IA
Click here to add this to my saved trials
Atlanta, Georgia 30046
?
mi
from
Atlanta, GA
Click here to add this to my saved trials
13123 E 16th Ave
Aurora, Colorado 80045
(720) 777-1234
Principal Investigator: Bradley Dixon
Children's Hospital Colorado At Children's Hospital Colorado, we see more, treat more and heal more...
?
mi
from
Aurora, CO
Click here to add this to my saved trials
Baltimore, Maryland 21287
Principal Investigator: John Sperati
?
mi
from
Baltimore, MD
Click here to add this to my saved trials
Bethlehem, Pennsylvania 18017
?
mi
from
Bethlehem, PA
Click here to add this to my saved trials
London, SW7 2AZ
Principal Investigator: Matthew Pickering
?
mi
from
London,
Click here to add this to my saved trials
550 1st Avenue
Queens, New York 11040
Principal Investigator: Howard Trachtman
?
mi
from
Queens, NY
Click here to add this to my saved trials
200 First Street SW
Rochester, Minnesota 55905
507-284-2511
Principal Investigator: Fernando Fervenza
Mayo Clinic Rochester Mayo Clinic is a nonprofit worldwide leader in medical care, research and...
?
mi
from
Rochester, MN
Click here to add this to my saved trials